文献速递消化系统肿瘤

改良XELIRI对比FOLFIRI联合或不联合贝伐珠单抗二线治疗转移性结直肠癌:AXEPT研究

Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2018-03-16

AXEPT是一项多中心、开放标签、随机、非劣效性3期试验,纳入650例转移性结直肠癌患者,比较mXELIRI与FOLFIRI(均联合或不联合贝伐珠单抗)二线治疗。mXELIRI组3-4级中性粒细胞减少发生率更低(17% vs 43%),但3-4级腹泻更高(7% vs 3%)。

要点

  • mXELIRI组3-4级中性粒细胞减少发生率显著低于FOLFIRI组。
  • mXELIRI可作为亚洲转移性结直肠癌二线治疗FOLFIRI的替代方案。

核心结论

  • mXELIRI联合或不联合贝伐珠单抗在总生存方面非劣效于FOLFIRI联合或不联合贝伐珠单抗,且耐受性良好。
  • mXELIRI可作为转移性结直肠癌标准二线骨架治疗的替代选择,至少对亚洲患者群体如此。

研究设计与样本

  • 多中心、开放标签、随机、非劣效性3期试验,在日本、中国和韩国的98家医院纳入650例患者。
  • 患者按1:1随机分配至mXELIRI组(n=326)或FOLFIRI组(n=324),均联合或不联合贝伐珠单抗。

主要发现

  • 最常见3-4级不良事件为中性粒细胞减少:mXELIRI组52/310例(17%),FOLFIRI组133/310例(43%)。
  • 3-4级腹泻发生率mXELIRI组22/310例(7%),FOLFIRI组10/310例(3%)。
  • 严重不良事件mXELIRI组46/310例(15%),FOLFIRI组63/310例(20%);治疗相关死亡mXELIRI组2例(肺炎和肺部感染),FOLFIRI组1例(肺部感染)。

关键数值与推荐

  • FOLFIRI方案:伊立替康180 mg/m2静脉第1天,亚叶酸钙200 mg/m2静脉第1天,氟尿嘧啶400 mg/m2静脉第1天,氟尿嘧啶2400 mg/m2持续静脉输注46小时,每14天重复,联合或不联合贝伐珠单抗5 mg/kg静脉第1天。

临床怎么用

  • 对于转移性结直肠癌二线治疗,mXELIRI联合或不联合贝伐珠单抗可作为FOLFIRI方案的替代选择。
  • mXELIRI组中性粒细胞减少发生率较低,但需注意腹泻发生率较高。
  • 该方案尤其适用于亚洲患者群体。

局限性

  • 研究为开放标签设计,患者和研究者未对治疗分配设盲。
  • 研究人群仅限日本、中国和韩国患者,结论外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies of a modified XELIRI (mXELIRI; capecitabine plus irinotecan) regimen suggest promising efficacy and tolerability profiles in the first-line and second-line settings. Therefore, we aimed to compare the efficacy and safety of the mXELIRI regimen with that of standard FOLFIRI (leucovorin, fluorouracil, and irinotecan), with or without bevacizumab in both regimens, as a second-line therapy for metastatic colorectal cancer. METHODS: We did a multicentre, open-label, randomised, non-inferiority, phase 3 trial. We enrolled patients from 98 hospitals in Japan, China, and South Korea who were aged 20 years or older with histologically confirmed and unresectable colorectal adenocarcinoma, and who had withdrawn from first-line chemotherapy for metastatic colorectal cancer. We randomly assigned patients (1:1) to receive either mXELIRI with or without bevacizumab (irinotecan 200 mg/m2 intravenously on day 1 plus oral capecitabine 800 mg/m2 twice daily on days 1-14, repeated every 21 days, with or without bevacizumab 7·5 mg/kg intravenously on day 1) or FOLFIRI with or without bevacizumab (irinotecan 180 mg/m2 intravenously on day 1, leucovorin 200 mg/m2 intravenously on day 1, fluorouracil 400 mg/m2 intravenously on day 1, and a 46-h continuous intravenous infusion of fluorouracil [2400 mg/m2], repeated every 14 days, with or without the addition of bevacizumab 5 mg/kg intravenously on day 1) via a centralised electronic system. We used the minimisation method to stratify randomisation by country, Eastern Cooperative Oncology Group performance status, number of metastatic sites, previous oxaliplatin treatment, and concomitant bevacizumab treatment. Patients and clinicians were not masked to the allocated treatment. The primary endpoint was overall survival analysed on an intention-to-treat basis with a non-inferiority upper margin of 1·30 for the hazard ratio (HR). This study is registered with ClinicalTrials.gov, number NCT01996306, and is ongoing but no longer recruiting participants. FINDINGS: Between Dec 2, 2013, and Aug 13, 2015, 650 patients were enrolled and randomly assigned to receive mXELIRI with or without bevacizumab (n=326) or FOLFIRI with or without bevacizumab (n=324). After a median follow-up of 15·8 months (IQR 8·7-24·9), a total of 490 patients had died (242 in the mXELIRI with or without bevacizumab group and 248 in the FOLFIRI with or without bevacizumab group) and the median overall survival was 16·8 months (95% CI 15·3-19·1) in the mXELIRI group and 15·4 months (13·0-17·7) in the FOLFIRI group (HR 0·85, 95% CI 0·71-1·02; pnon-inferiority<0·0001). In the per-protocol safety population, the most common grade 3-4 adverse event was neutropenia (affecting 52 [17%] of 310 patients in the mXELIRI group and 133 [43%] of 310 in the FOLFIRI group). Incidences of grade 3-4 diarrhoea were higher in the mXELIRI group (22 [7%]) than in the FOLFIRI group (ten [3%]). Serious adverse events were reported in 46 (15%) of 310 patients in the mXELIRI group and 63 (20%) of 310 in the FOLFIRI group. Two treatment-related deaths (one pneumonitis and one lung infection) were observed in the mXELIRI group and there was one treatment-related death (lung infection) in the FOLFIRI group. INTERPRETATION: mXELIRI with or without bevacizumab is well tolerated and non-inferior to FOLFIRI with or without bevacizumab in terms of overall survival. mXELIRI could be an alternative to FOLFIRI as a standard second-line backbone treatment for metastatic colorectal cancer, at least for Asian patient populations. FUNDING: Chugai Pharmaceutical and F Hoffmann-La Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Xu RH, Muro K, Morita S, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2018. PMID: 29555258. doi:10.1016/S1470-2045(18)30140-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。